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Objectives: Prolonged exposure to CNI-based immunosuppressant therapy (IS) 
in liver transplant (LTx) recipients is associated with long-term complications. 
In the global registration trial H2304, patients receiving everolimus + reduced 
tacrolimus (EVR + reduced TAC) demonstrated non-inferior efficacy and supe-
rior renal function at Month 12 that was sustained at 36 months compared to 
tacrolimus alone (TAC). A peer-reviewed Markov model has been adapted to the 
Italian setting to explore the cost-effectiveness of EVR + reduced TAC compared to 
TAC, in de novo liver-recipients. MethOds: The model estimates long-term out-
comes associated with IS following LTx along two independent pathways: 1. liver-
related (acute rejection, hepatocellular carcinoma, hepatitis C [HCV] recurrence, 
graft loss); 2. kidney-related (chronic kidney disease, dialysis, renal transplanta-
tion) and death. All patients, stratified by liver diagnosis, entered the model at time 
of LTx and followed both pathways, allowing for multiple combinations of liver 
and kidney health states. The lifetime model used an annual cycle length 
except for the 1styear post LTx (quarterly). Efficacy and safety of IS strategies 
were assessed through the risk of acute rejection, change in renal function, HCV 
fibrosis progression and frequency of adverse events. Utilities and costs were 
assigned to each renal and liver state. Subgroup and sensitivity analyses were 
performed. Results: With a mean life expectancy of 18 years, the model predicts 
patients treated with EVR + reduced TAC gain on average 1.84 years of life and 1.55 
QALYs vs. TAC. The risk of acute rejection was reduced by 20%. The incremental 
cost of EVR + TAC was € 38,884 per life year gained and € 46,103 per QALY gained 
vs. TAC. cOnclusiOns: This model shows a strategy of EVR + reduced TAC post- 
LTx improves survival and quality of life. Higher treatment costs are offset by 
slower progression of renal deterioration predicted in the first 10 years and fewer 
lifetime liver complications.
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Objectives: Nonalcoholic fatty liver disease (NAFLD) is the most common liver 
condition in Western countries. To date, no studies have examined the cost-
effectiveness of screening for nonalcoholic steatohepatitis (NASH), its advanced 
form. MethOds: We performed a cost-utility analysis of annual non-invasive 
screening strategies using a third-party payer perspective in a general population 
and compared it to screening in a high-risk obese or diabetic population. Screening 
algorithms involved well-studied non-invasive techniques including NAFLD fibro-
sis score, ultrasound transient elastography (TE), and ultrasound acoustic radiation 
force impulse (ARFI) imaging for detecting advanced fibrosis (≥ F3); and plasma 
cytokeratin-18 for NASH detection. Liver biopsy and magnetic resonance elas-
tography (MRE) were compared as confirmation methods. Model uncertainties 
were tested using sensitivity analyses. Canadian dollar costs were adjusted for 
inflation and discounted at 5%. Incremental cost-effectiveness ratio (ICER) of 
$C50,000 per quality-adjusted life year (QALY) or less was considered cost-effec-
tive. Results: Compared with no screening, screening with NAFLD fibrosis score/
TE/CK-18 algorithm with MRE as confirmation for advanced fibrosis had an ICER 
of $C26,143 per QALY gained. Screening in high-risk obese or diabetic populations 
was more cost-effective, with an ICER of $C9,051 and $C7,991 per QALY gained 
respectively. Screening algorithms with liver biopsy confirmation were not found 
to be cost-effective. Sensitivity analyses revealed that the screening starting age, 
the annual transition probability from simple steatosis to NASH, and the cost of 
a TE exam had the most impact on the results. cOnclusiOns: Our model sug-
gests that annual NASH screening in high-risk obese or diabetic populations can 
be cost-effective.
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Objectives: Sofosbuvir in combination with ribavirin (SOF/RBV) is a novel treat-
ment able to suppress HCV viremia when applied to HCV patients listed for 
transplant, preventing HCV recurrence. Aim of this study was to assess the cost-
effectiveness of this regimen in HCV patients listed for transplant for cirrhosis (HCV-
cirrhosis) or for hepatocellular carcinoma (HCV-HCC). MethOds: a semi-Markov 
model was developed. The model simulates the progression of HCV-cirrhosis or 
HCV-HCC patients from the time of listing until death considering the risk of HCV 
recurrence post-transplant. The model compared 2 different strategies: 1) SOF/RBV 
up to a maximum of 24 weeks or until OLT if performed before the 24th week, 2) 
No antiviral treatment. The model estimated the costs related to the treatment 
with SOF/RBV, the costs associated to each health state, the life-years (LYSs), the 
quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio 
(ICER) expressed as € per QALY gained. The analysis was performed from the Italian 
National Health System perspective with a lifetime time horizon and one-month 
Markov cycles. Future costs and clinical benefits, expressed as QALYs, were dis-
counted at 3% per year. Results: in the base-case analysis the ICER for 24 weeks 
of SOF/RBVR was € 30,518 per QALY gained in HCV-cirrhosis patients and € 41,610 
in HCV-HCC patients. The reliability of our results was confirmed by the one way 
sensitivity-analysis and by the cost-effectiveness acceptability curve. Further, SOF/
RBV cost-effectiveness was clearly sensitive to the duration of treatment; assum-
ing 12 weeks SOF/RBV treatment duration, the ICER decreased to € 19,317 in HCV-
Cirrhosis and € 29,540 in HCV-HCC. cOnclusiOns: our study shows that treating 
patients with HCV-cirrhosis or HCV-HCC listed for transplant with SOF/RBV is cost-
effective and may become the new standard of care for these patients. However a 
well-defined prospective study is needed to confirm the value of the parameters 
assumed in the model and the results.
LY was calculated. Sensitivity analyses were performed. Results: Model results for 
treatment-experienced patients show that SMV is the dominant treatment com-
pared to TVR+PR and BOC+PR therapies as more total LYs are saved and less costs 
accrued. ICER of SMV+PR vs PR was € 22,967 per LY. Results were robust in sensitivity 
analyses. cOnclusiOns: SMV + PR is cost-effective compared to dual PR-therapy 
and appears the dominant strategy compared to other PI (telaprevir, boceprevir) for 
CHC treatment-experienced patients in Russia.
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Objectives: Studies based on the data of clinical trials have proved that the triple 
therapy for hepatitis C is cost effective. This study we assessed the cost-effective-
ness of triple therapy in treatment of Chronic Hepatitis C with Severe Fibrosis under 
“real-life” conditions. MethOds: The analysis was conducted from the data included 
in the prospective, multicentre, Spanish registry that includes patients with HCV-
genotype-1 infection, who had severe fibrosis and were treated with triple therapy 
(peginterferon alfa-2a or 2b, ribavirin, and boceprevir). The cost effectiveness analysis 
of antiviral treatment includes the costs of antiviral treatment, of concomitant treat-
ments and costs in relation to health care resources (in relation to clinical practice 
and the adverse events). Results: 170 patients were included. 68.2% male, mean 
age of 53 (29-76) years. 80% had received prior treatment. 36.5% of patients reported 
at least one SAEs. The overall percentage of patients with SVRw12 was 46.5%. The 
cost of triple therapy represented a total of 4,916,652.84€ , the pharmacological cost 
(triple therapy+concomitant treatment) involved a total cost of 5,161,168.98€ . The 
consumption of health resources generated an additional cost of 240,000 € , which is 
about 1,500€ /patient. The total cost per patient cured was 70,262€ . This cost varies 
greatly based on different baseline characteristics of the patients, with significant 
differences in patients with albumin < 3.5, 120,597€ ; prior null response 120,727€ and 
platelets < 90,000,104,464€ . cOnclusiOns: The current scenario of the hepatitis C 
treatment is changing. Triple therapy is more costly for patients with severe fibrosis 
and predictors of poor response. However, keeping in mind that the timeframe for the 
release of IFN-free regimens remains uncertain and considered that the actual access 
to the new DAA in the real world setting could be delayed, boceprevir could remain 
as an option for patients with intact liver function and a high unmet medical need, 
regardless of the degree of liver fibrosis, in locations where a delay in the access to 
the newer therapies is foreseen and hepatic transplant would not be readily available.
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Objectives: The aim of this study is to compare the cost effectiveness of oral anti-
viral treatment strategies in CHB for Turkey using lamuvidine, telbuvidine, entecavir, 
and tenofovir as medications. MethOds: The analysis was conducted using Markov 
model. Inadequate response or resistance after receiving 12 months of the treatment 
with entecavir and telbivudine were compared to the results found from switching 
from entecavir to tenofovir or from switching from telbuvidine to tenofovir. In addi-
tional, inadequate response or resistance after receiving 6 months of the treatment 
for lamivudine was compared to the results found from switching from lamivudine 
to tenofovir. The model duration was constructed to evaluate a treatment strategy 
duration of 40 years. Years of Potential Life Lost (YPLL) was used as the health 
outcome. An incremental cost-effectiveness ratio (ICER) analysis of the results was 
conducted. Results: In a life time period, the lowest YPLL and the cost of treatment 
were calculated for the NS. Tenofovir treatment with 0.54 years and 37,213.75 TL. 
Depending on the results, the lowest YPLL and the cost of treatment were served 
by NS. Tenofovir treatment with 2.06 years and 276,468.45 TL. The highest YPLL and 
the cost of treatment were calculated for the NS. The ICER analysis found that all 
treatment strategies were dominated by NS. Tenofovir and S. Entecavir. Only these 
two treatment strategies were found to be cost-effective. cOnclusiOns: The cost 
of providing 40 years of treatment for patients with CHB, if reimbursement agen-
cies includes Tenofovir and Entecavir as part of the first line treatment strategy for 
CHB, it can be expected that this approach would result in a positive contribution 
to the health budget in Turkey.
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(63.4%). Five studies were related to digestive cancers and other included peptic 
diseases, hernias and other. cOnclusiOns: There was a considerable increase in 
publications of economic evaluations in Gastroenterology in Brazil, being mostly 
studies of drugs for treatment of viral hepatitis. The high cost of these treatments 
and increased of lawsuits seem to account for this increase.
PGI33
estImAtInG the Cost of lIver trAnsPlAntAtIon In PAtIents dIAGnosed 
WIth ChronIC hePAtItIs C And b In the Uk
Singh J., Longworth L.
Brunel University, Uxbridge, UK
Objectives: Liver transplantation is an effective treatment option for end-stage 
liver disease and acute liver failure, including patients with hepatitis C (HCV) and 
hepatitis B (HBV). Recent health technology assessments of treatments for HCV 
and HBV have relied on data from a large cohort study of transplanted patients to 
inform estimates of costs of liver tranplantations; however this was conducted in 
the 1990s. The overall aim of this study was to estimate the current cost of liver 
transplant for patients with HCV and HBV in the UK. MethOds: Historical sum-
mary data from the original cohort study were updated to reflect current unit costs 
and key changes in clinical practice. Semi-structured interviews were conducted 
with experts and a computer-based user-interface was developed to elicit estimates 
of key resource use items. Uncertainty in the experts’ estimates was captured by 
eliciting probability distributions for each item from each expert. Updated unit costs 
were obtained from national sources. Data were analysed by phase of the transplant 
procedure. Results: The expert elicitation exercise included two hepatologists, 
three transplant surgeons and one liver transplant coordinator. Few patients with 
HBV are now being transplanted due to improvements in anti-viral treatments. 
Mean total costs for patients with HCV were £18,055 pre-transplantation, £64,452 
during the transplant phase and £36,009 in two years post-transplant. The average 
cost per transplanted patient with HCV from assessment to two years post-trans-
plant is £111,810. cOnclusiOns: There have been some significant changes in 
clinical practice since the original study such as change in standard immunosup-
pressant therapy, more patients with co-morbidities being placed on the transplant 
waiting list, increased use of sub-optimal organs and reluctance to re-transplant 
patients with graft failure and recurrence of HCV.
GAstroIntestInAl dIsorders – Patient-reported outcomes & Patient  
Preference studies
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Objectives: Prior to approval of telaprevir (TPV), the treatment for chronic hepatitis 
C virus (HCV) included peginterferon (P) weekly injections and ribavirin (R) orally 
twice daily. In 2011, TPV was approved for coadministration with P+R during the 
first 12 weeks. Though TPV improved viral clearance, it also increased the treat-
ment complexity by 2 pills given 3 times a day. The impact of increased regimen 
complexity on adherence is not well understood. This study compared treatment 
adherence over 24 weeks in HCV patients treated with TPV+PR compared to those 
on PR. MethOds: Large US commercial and Medicaid health insurance claims 
databases were used to identify HCV patients initiating treatment with PR (pre-TPV 
[2007 to 2009]) or TPV+PR (post-TPV [2011 to 2013]). The index date was the date of 
HCV treatment initiation. Adherence was measured by medication possession ratio 
for all patients at 4 week intervals thru 24 weeks. Regression analyses adjusted for 
age, sex, comorbidities, liver disease severity, and pill count prior to HCV treat-
ment. Results: The study included 7,601 and 1,487 treated HCV patients in the 
commercial and Medicaid databases. Unadjusted and adjusted adherence was high 
for both cohorts throughout the study period (> 88% for Medicaid and > 82% for the 
commercial at 24 weeks). Adherence was not significantly different between the 
PR and T+PR cohorts at any time point in the Medicaid patients (88.9% [TPV+PR] 
and 90.5% [PR] at 24 weeks). Adherence was also similar between the cohorts in the 
commercial patients (82.7% [TPV+PR] and 83.2% [PR] at 24 weeks) but was statisti-
cally different at weeks 8 and 12, though not clinically meaningful. Age was the 
only factor consistently associated with adherence. cOnclusiOns: Among HCV 
patients, adherence rates were high and were similar between the cohorts, despite 
the higher daily pill count for patients on TPV+PR.
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Objectives: To estimate the utility scores for diarrheal children aged under 5 
years and their caregivers and to identify the influencing factors which affected 
on these. MethOds: Hospitalized diarrheal children aged between 2 months and 
5 years and their caregivers at were recruited in this cross-sectional study at three 
hospitals in Phetchabun province. The EQ-5D instrument was used to collect the 
quality of life (QoL) data at the first date of admission. Quality of life of diarrheal 
children was measured as proxy report from caregiver while QoL of caregiver was 
measured as self-report. The raw data was converted to utility values using the Thai 
algorithm. The clinical severity of diarrheal children was rated using the Vesikari 
clinical severity scoring system. Stepwise multivariate linear regression was applied 
to explore the impact of the various factors on the utility value of children and 
PGI30
Cost-UtIlIty AnAlysIs of sofosbUvIr for treAtment of GenotyPe2 
ChronIC hePAtItIs C In JAPAn
Igarashi A.1, Tang W.1, Cure S.2, Guerra I.2, Lopresti M.3, Tsutani K.1
1University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, 2OptumInsight, 
Uxbridge, UK, 3Junicon Japan Inc., Minato Tokyo, Japan
Objectives: To conduct a cost-utility analysis of sofosbuvir for genotype 2 
chronic hepatitis C virus (HCV) infection in Japan. MethOds: The Markov-model, 
“Sofosbuvir cost-effectiveness model”, which was constructed originally for similar 
study in UK, was modified and used for this analysis, while imputed data were 
replaced with Japanese data, as far as possible. Various health states, such as non-
cirrhotic hepatitis, sustained virological response (SVR), compensated cirrhosis, 
decompensated cirrhosis and hepatocellular carcinoma were incorporated to the 
model. Analyses were conducted for 4 scenarios, classified by treatment history 
(naive/experienced) and eligibility for interferon. Peg-interferon alpha with ribavirin 
was set as a comparator for those who were eligible for interferon. No treatment 
was selected for those who were not eligible for interferon. Probability of SVR was 
derived from clinical trials conducted in Japan. Other transition probabilities and 
utility scores of each health state were obtained from published data in Japan. 
Cost data for interferon-alpha and ribavirin were derived from national drug tariff 
(2014). For sofosbuvir, average European price was adopted since it was not yet 
approved in Japan. Other cost data, such as costs related to health states, were 
mainly obtained from claim data, provided by JMDC (Japan Medical Data Center). 
Inc. Time-horizon was set to lifetime. Costs and outcomes were discounted with 2% 
per annum, according to Japanese guideline. Results: For interferon-unsuitable 
patients, sofosbuvir was dominant to no-treatment. Sofosbuvir would save overall 
costs for JPY990,000 (USD9,900, JPY100= USD1) and prolonged 6.20QALY for treat-
ment naive patients. It would save JPY 837,000 and prolonged 6.08QALY for treat-
ment experienced group, For interferon-suitable patients, sofosbuvir would increase 
overall costs for JPY3,270,000 and prolonged 2.23QALY for treatment-naives. It would 
increase JPY1,551,000 and prolonged 2.36QALY for treatment-experienced. ICER 
were JPY1,470,000 and JPY657,000 per QALY gained, respectively. cOnclusiOns: 
Sofosbuvir was considered to be cost-effective for treatment of genotype-2 HCV 
patients in Japan.
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Objectives: In recent years a number of infections caused by Clostridium difficile 
has been significantly increasing. In Poland oral metronidazole constitutes the ther-
apy of choice of non-severe infection and first-recurrence, while oral vancomycin 
is recommended to be given in case of severe disease and subsequent recurrences. 
Fidaxomicin is a novel treatment for Clostridium difficile infections (CDI). The aim 
of this study was to perform a cost-utility analysis of fidaxomicin for the treatment 
of severe CDI compared to vancomycin. MethOds: A meta-analysis of two ran-
domized clinical trials phase III comparing oral fidaxomicin and oral vancomycin 
in CDI was conducted. A Markov model was used to determine the cost-utility of 
fidaxomicin in patients with severe CDI. The cycle length was 10 days and the time 
horizon was 1 year. The patient entered the model in the severe CDI health state 
and was given either fidaxomycin or vancomycin for 10 days. The analysis was 
performed from the third-party payer perspective – the Polish National Health Fund. 
Only direct health care costs (drug costs, hospitalization) were included. Given the 
lack of formal utility measures for CDI, the utilities for the alternative health states 
described in the literature were adapted. Results: In the base case, fidaxomicin 
was dominant compared to vancomycin, resulting in cost savings of PLN 905 and 
an incremental QALY gain of 0.015. Fidaxomicin was associated with higher cost 
savings (PLN 30,883) assuming that patients with severe CDI would be hospital-
ized at intensive care unit. One-way sensitivity analyses revealed that fidaxomicin 
remained dominant even if considering marginal values of both antibiotics’ acqui-
sition cost. cOnclusiOns: Fidaxomicin was dominant compared to vancomycin, 
generating additional QALYs with cost-savings in severe CDI patients in Poland.
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Objectives: The aim of this study was to systematically review the economic 
assessment studies carried out in Brazil, published between January 1980 and 
December 2013, assessing the technologies studied, study types, the and tem-
poral evolution and quality. MethOds: We systematically searched in MEDLINE 
(PubMed), EMBASE, LILACS, SciELO, NHS EED, HTA Database (CRD), BVS ECOS, 
SCOPUS, Web of Science, and SISREBRATS. We selected partial and full economic 
evaluation studies in gastroenterology, where at least one of the authors was affili-
ated to a Brazilian institution. Two authors performed study selection and data 
extraction independently. Disagreements were resolved through discussion or 
through consultation with a third reviewer. The study characteristics were sum-
marized in figures and summary tables. Results: Forty studies were included. The 
first studies were published in the 80s, but most occurred after 2000, with greater 
frequency in the last 4 years. Seventeen economic evaluations were incomplete 
(42.5%) and 23 complete (57.5%). In the 23 complete reviews, 11 (47.8%) studies 
were cost-utility analysis, 7 (30.4%) were cost-effectiveness analysis, 4 (17.4%) cost-
consequence analysis, and 1 (4.3%) cost-minimization analysis. The type of technol-
ogy evaluated was mainly medications in 25 studies (62.5%), 7 (17.5%) medical and 
surgical procedures, 3 (7.5%) medical and hospital equipment, 1 (2.5%) vaccines and 
4 (10%) evaluated more than one type of technology. When classified by disease, 22 
(55%) were studies on viral hepatitis, and in its most published after the year 2010 
